Clinical trials located in


Newcastle city is located in United Kingdom. Currently, 3 clinical trials are being conducted in this city.

  • CT-EU-00119004

    Testing Vemurafenib and Cobimetinib for BRAF Positive Cancers

    This clinical trial is for patients with cancers that have a specific change in their cancer cells known as BRAF V600 mutation. It uses two drugs, vemurafenib and cobimetinib, to see if they can effectively treat various types of cancers such as solid tumors, haematological malignancies, melanoma, thyroid cancer, ovarian neoplasms, colorectal neoplasms, laryngeal neoplasms, non-small-cell lung carcinoma, glioma, multiple myeloma, and Erdheim-Chester disease. The purpose of this study is to determine if these drugs can help treat cancers with the BRAF V600 mutation.

    In the study, participants will receive both drugs until their disease progresses, they experience unacceptable side effects, or they decide to withdraw. Blood samples will be collected at different times during the treatment for research purposes. Participants will be monitored every three months for two years after completing the treatment.

    • Vemurafenib
    • Cobimetinib
  • A study on the use of the new drug NX-1607 for patients with advanced types of various cancers

    The main goal of this study is to test the safety and effectiveness of a new drug called NX-1607 in the treatment of various types of advanced cancers. NX-1607 is taken orally and works by blocking a protein called Cbl-b.

    The study consists of two parts. The first part, called Phase 1a, will study different doses of NX-1607 alone or in combination with paclitaxel to find the highest safe dose. This section includes patients with cancers such as ovarian, stomach, head and neck, melanoma, lung, prostate, mesothelioma, breast, bladder, cervical, colorectal and lymphoma.

    In the second part, called Phase 1b, selected doses from Phase 1a will be administered to separate groups of patients with the same type of cancer. The main goal is to see if NX-1607, alone or with paclitaxel, can shrink or control tumors. Patient safety will be continuously monitored by researchers.

    The goal of this study is to find the right dose of the experimental drug NX-1607 and see if it has promising anti-cancer effects in a variety of advanced cancers for which treatment options are limited. Patient safety is the highest priority throughout the entire examination.

    • NX-1607
    • Paclitaxel
  • Exploring EDG-5506 for Becker Muscular Dystrophy

    The GRAND CANYON study is part of a larger research effort to explore the potential benefits of a new medication called EDG-5506 for individuals with Becker Muscular Dystrophy. This medication is taken orally, once a day, and comes in different doses. The study aims to understand how safe and effective EDG-5506 is in treating this condition.

    Previously, a segment of this research, known as CANYON, was conducted and has now successfully enrolled all its participants. Building on this, the GRAND CANYON study is currently inviting adults with Becker Muscular Dystrophy to join this next phase. This part of the study is designed to be very thorough, involving a double-blind method where neither the participants nor the researchers know who is receiving the actual medication or a placebo. This approach helps ensure the results are unbiased and reliable.

    Participants in the GRAND CANYON study will be randomly assigned to either receive EDG-5506 or a placebo, with a higher chance of receiving the actual medication. The study spans over an 18-month treatment period, with a 4-week screening phase before the treatment starts and a 4-week follow-up period after the treatment ends.

    The main focus of the study is to monitor any adverse events or side effects from taking the medication, as well as its overall safety. Additionally, the study will look at changes in specific health markers, like serum Creatine Kinase, and functional measures, such as the North Star Ambulatory Assessment scale, to gauge the medication’s effectiveness.

    • EDG-5506

See more clinical trials in other cities in United Kingdom: